Little is known about the impacts of therapy on adolescent patients with T2DM. In a recent study, adolescents with newly diagnosed T2DM had profound impairment of beta-cell function, but treatment ...
Biomea Fusion, Inc. announced positive results from preclinical experiments showing that its investigational drug icovamenib enhances beta cell function and improves the responsiveness of human islets ...
Scientists have discovered that human stomach cells can be genetically reprogrammed to act like pancreatic beta cells and ...
Therapeutic effects were sustained off treatment, with persistent reduction in HbA1c and improvement in beta-cell function 3 months after last dose, suggesting disease-modifying potential of ...
The old antihypertensive drug verapamil may help reduce insulin requirements and hypoglycemic episodes in adults with type 1 diabetes, new research suggests. Results from the study were published ...
Discover how new diabetes subgroups are reshaping treatment and diagnosis. Learn how personalised care could improve outcomes for people with diabetes.
Biomea Fusion, Inc. has presented promising clinical results for icovamenib, a novel therapy aimed at restoring beta-cell function in patients with type 2 diabetes, at the ATTD 2025 Conference.
In recent years, we have come to appreciate that loss or dysfunction of insulin-producing islet beta cells underlies virtually all major forms of diabetes mellitus. In type 1 diabetes, beta cells ...
Type 1 diabetes is caused by an insufficient production of the hormone insulin by cells in the pancreas called beta cells and ...
Researchers genetically engineered stomach organoids to transform them into pancreatic beta cells capable of secreting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback